Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: Just a marketing ‘gag’?

This publication has 35 references indexed in Scilit:

• PEG IFN α 2b 1.0 mcg/kg/wk + ribavirin is equally as effective as PEG IFN α 2b 1.5 mcg/kg/wk + ribavirin: Preliminary results from a prospective randomized, controlled, multi-center trial
  Gastroenterology, 2003
• Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
  Gastroenterology, 2002
• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2002
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
  Published by Elsevier ,2001
• A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
  Hepatology, 2001
• Efficacy and Safety of Pegylated (40–Kd) Interferon α–2A Compared With Interferon α–2A in Noncirrhotic Patients With Chronic Hepatitis C
  Hepatology, 2001
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
  Science, 1998
• HOW CELLS RESPOND TO INTERFERONS
  Annual Review of Biochemistry, 1998
• Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfa
  Hepatology, 1998
• Signal transduction pathways in the induction of 2',5'-oligoadenylate synthetase gene expression by interferon alpha/beta.
  Proceedings of the National Academy of Sciences, 1989